Today, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule that describes the agency’s proposed actions to remedy the payment for 340B drugs for calendar years (CYs) 2018 through 2022 (press release).  What is it. In June 2022, the Supreme Court ruled that CMS’s differential payment of the average sales price (ASP) minus 22.5 percent for 340B drug was unlawful because… (Slifer, July 7, 2023) #340B